Researchers went on to investigate 996 breast cancer patients receiving neoadjuvant chemotherapy and showed that CXCL13 expression was highly correlated with complete remission in HER2 patients (41), a finding that could help in the development of new immunotherapies. The gene discussed is ERBB2; the disease is breast cancer.